Docoh
Loading...

GSK Glaxosmithkline

Filed: 21 Feb 20, 8:23am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs V Whyte
b)Position/statusCompany Secretary
c)Initial notification/amendmentInitial Notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionTransfer of 10,720 Ordinary Shares between accounts for nil consideration.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.0010,720 
    
d)Aggregated informationN/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-02-20
f)Place of the transactionN/A

 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs V Whyte
b)Position/statusCompany Secretary
c)Initial notification/amendmentInitial Notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transaction
Transfer of 10,838 Ordinary Shares to spouse for nil consideration.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.0010,838 
    
d)Aggregated informationN/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-02-20
f)Place of the transactionN/A
 
 
 
 Details of PDMR/person closely associated with them ('PCA')
a)NameMr I Whyte
b)Position/statusPCA of Ms V Whyte (Company Secretary)
c)Initial notification/amendmentInitial Notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial  instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionReceipt of 10,838 Ordinary Shares from spouse for nil consideration.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.0010,838 
    
d)Aggregated informationN/A (single transaction)
Aggregated volume Price 
e)Date of the transaction2020-02-20
f)Place of the transactionN/A
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: February 21, 2020 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc